Prospectief multicentrisch farmacokinetisch onderzoek: Invloed van mesalazine op het thiopurinemetabolisme bij patiënten met inflammatoire darmziekten

Dennis R. Wong(Zuyderland Medisch Centrum), P. M. Hooymans(Maaslandziekenhuis), Nanne K.H. de Boer, Adriaan A. van Bodegraven(Maastricht University Medical Centre), Peer de Graaf(American Pharmacists Association), Bindia Jharap(Meander Medisch Centrum)

Pure Amsterdam UMC

March 21, 2008

Cited by 0

Related Papers

Loss of Response to Anti-TNFs: Definition, Epidemiology, and Management

|Clinical and Translational Gastroenterology|2016|724

Ustekinumab versus adalimumab for induction and maintenance therapy in biologic-naive patients with moderately to severely active Crohn's disease: a multicentre, randomised, double-blind, parallel-group, phase 3b trial

|The Lancet|2022|301

Infants born to mothers with IBD present with altered gut microbiome that transfers abnormalities of the adaptive immune system to germ-free mice

|Gut|2019|221

Identification of Patients With Variants in TPMT and Dose Reduction Reduces Hematologic Events During Thiopurine Treatment of Inflammatory Bowel Disease

|Gastroenterology|2015|199

Thiopurine therapy in inflammatory bowel disease patients: Analyses of two 8-year intercept cohorts

|Inflammatory Bowel Diseases|2010|199